<?xml version="1.0" encoding="UTF-8" ?>
<rss version="2.0">
<channel>


<title>aktiencheck.de - Forum - Vivus</title>
<link>http://www.aktiencheck.de</link>
<description>aktiencheck.de</description>
<language></language>
<copyright>aktiencheck.de</copyright>
<lastBuildDate>Sat, 18 Apr 2026 00:56:10 +0200</lastBuildDate>
<ttl>2</ttl>










<item>
<title>VIVUS auf Erfolgskurs...</title>
<link>http://www.aktiencheck.de/forum/VIVUS_auf_Erfolgskurs-A2N5RJ-t255736</link>
<guid>http://www.aktiencheck.de/forum/VIVUS_auf_Erfolgskurs-A2N5RJ-t255736</guid>
<description>VIVUS Announces FDA Acceptance of EvaMist(TM) NDA, VIVUS Announces FDA Acceptance of EvaMist(TM) NDA Submission
EvaMist(TM) is an Investigational Drug for the Treatment of Menopausal Symptoms

MOUNTAIN VIEW, Calif., Dec. 12 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS), a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products addressing obesity and sexual health, today announced that the new drug application (NDA) filed by the company for EvaMist(TM) was accepted for review by the U.S. Food and Drug Administration (FDA) as a new treatment for vasomotor symptoms associated with menopause.

VIVUS announced positive results from its pivotal Phase 3 clinical trial of EvaMist earlier this year. The study showed a statistically significant reduction in the number and severity of moderate and severe hot flashes for all three doses tested.

EvaMist is a novel, once-a-day, proprietary, first-in-class, transdermal spray that delivers [&lt;a href=&#034;http://www.aktiencheck.de/forum/VIVUS_auf_Erfolgskurs-A2N5RJ-t255736&#034;&gt;mehr&lt;/a&gt;]</description>
</item>







<item>
<title>Der Impotenzknüller :Vivus</title>
<link>http://www.aktiencheck.de/forum/Der_Impotenzknueller_Vivus-A2N5RJ-t223548</link>
<guid>http://www.aktiencheck.de/forum/Der_Impotenzknueller_Vivus-A2N5RJ-t223548</guid>
<description>PHASE III erfolgreich, VIVUS Announces Positive Phase 3 Clinical Trial Results for Evamist(TM) - The First Transdermal Spray for the Treatment of Menopausal Symptoms

Friday May 5, 8:00 am ET

Evamist, First Novel Transdermal Spray, Shows 78% Decrease in Moderate to Severe Hot Flashes

MOUNTAIN VIEW, Calif., May 5 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS - News) today announced positive results from the pivotal Phase 3 clinical trial of Evamist(TM). VIVUS' investigational estradiol metered dose transdermal spray is being developed for the treatment of vasomotor symptoms associated with menopause. The study showed a statistically significant reduction in the number and severity of moderate and severe hot flashes for all three doses tested. Evamist is a novel, once a day proprietary, first-in-class, transdermal spray that delivers estradiol, a naturally occurring estrogen, for the treatment of hot flashes in women. Evamist is a small, hand-held, simple-to-use spray that  [&lt;a href=&#034;http://www.aktiencheck.de/forum/Der_Impotenzknueller_Vivus-A2N5RJ-t223548&#034;&gt;mehr&lt;/a&gt;]</description>
</item>

</channel>
</rss>







